PMID- 11718213
OWN - NLM
STAT- MEDLINE
DCOM- 20020502
LR  - 20131121
IS  - 0392-9078 (Print)
IS  - 0392-9078 (Linking)
VI  - 20
IP  - 3
DP  - 2001 Sep
TI  - Anticipated administration of GM-CSF in the treatment of non small cell lung 
      cancer.
PG  - 345-9
AB  - The purpose of this study was to verify the kinetic response of the human marrow 
      myeloid progenitor cells to the short term use of GM-CSF and its impact on the 
      therapeutic activity of this three-drug cisplatinum containing regimen in non 
      small cell lung cancer (NSCLC). Sixty patients with stage III-B and IV NSCLC were 
      randomised to receive GM-CSF for 3 days, five days prior to the onset of 
      chemotherapy. The chemotherapy regimen consisted of Mitomycin-C: 6 mg/m2 on day 
      one, Ifosfamide: 2000 mg/m2 days 1 to 3, Mesna: 2000 mg/m2 days 1 to 3, 
      Cisplatinum: 30 mg/m2 days 1 to 3, and was repeated every 4 weeks. All the 
      patients received 30-50 Gy of radiotherapy to the primary and/or metastatic 
      sites. There were positive correlations between stage of the disease, 
      chemosensitivity of the tumor, number of chemotherapy cycles and overall survival 
      (p=0.000). Administration of GM-CSF was an independent prognostic parameter in 
      locally advanced and metastatic disease (p=0.041). In the GM-CSF receiving arm 
      more courses could be given (117 versus 99, p=0.0415), and less courses were 
      postponed (6 versus 22). In this arm, the mean of granulocyte nadir was higher 
      (p=0.033) and mean time to granulocyte recovery became shorter (p=0.001) as the 
      number of chemotherapy cycles increased. It was concluded that, dose 
      intensification with GM-CSF prophylaxis is benefical in increasing the treatment 
      tolerability by decreasing the intensity of granulocytopenia as well as providing 
      rapid recovery.
FAU - Erkisi, M
AU  - Erkisi M
AD  - Dept. of Medical Oncology, Cukurova University Medical School, Adana, Turkey.
FAU - Erkurt, E
AU  - Erkurt E
FAU - Zeren, H
AU  - Zeren H
FAU - Tunali, C
AU  - Tunali C
FAU - Kocabas, A
AU  - Kocabas A
FAU - Burgut, R
AU  - Burgut R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Exp Clin Cancer Res
JT  - Journal of experimental & clinical cancer research : CR
JID - 8308647
RN  - 0 (Recombinant Proteins)
RN  - 50SG953SK6 (Mitomycin)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
RN  - NR7O1405Q9 (Mesna)
RN  - Q20Q21Q62J (Cisplatin)
RN  - UM20QQM95Y (Ifosfamide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality/pathology/radiotherapy
MH  - Cisplatin/administration & dosage
MH  - Drug Administration Schedule
MH  - Female
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/*therapeutic use
MH  - Hematopoietic Stem Cells/pathology
MH  - Humans
MH  - Ifosfamide/administration & dosage
MH  - Lung Neoplasms/*drug therapy/mortality/pathology/radiotherapy
MH  - Male
MH  - Mesna/administration & dosage
MH  - Middle Aged
MH  - Mitomycin/administration & dosage
MH  - Recombinant Proteins
MH  - Survival Rate
EDAT- 2001/11/23 10:00
MHDA- 2002/05/03 10:01
CRDT- 2001/11/23 10:00
PHST- 2001/11/23 10:00 [pubmed]
PHST- 2002/05/03 10:01 [medline]
PHST- 2001/11/23 10:00 [entrez]
PST - ppublish
SO  - J Exp Clin Cancer Res. 2001 Sep;20(3):345-9.